Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer

To evaluate the prognostic significance of circulating tumour cell (CTC) number determined on the Epic Sciences platform in men with metastatic castration-resistant prostate cancer (mCRPC) treated with an androgen receptor signalling inhibitor (ARSI). A pre-treatment blood sample was collected from...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of cancer (1990) 2021-06, Vol.150, p.83-94
Hauptverfasser: Scher, H.I., Armstrong, A.J., Schonhoft, J.D., Gill, A., Zhao, J.L., Barnett, E., Carbone, E., Lu, J., Antonarakis, E.S., Luo, J., Tagawa, S., dos Anjos, C.H., Yang, Q., George, D., Szmulewitz, R., Danila, D.C., Wenstrup, R., Gonen, M., Halabi, S.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:To evaluate the prognostic significance of circulating tumour cell (CTC) number determined on the Epic Sciences platform in men with metastatic castration-resistant prostate cancer (mCRPC) treated with an androgen receptor signalling inhibitor (ARSI). A pre-treatment blood sample was collected from men with progressing mCRPC starting either abiraterone or enzalutamide as a first-, second- or third-line systemic therapy at Memorial Sloan Kettering Cancer Center (Discovery cohort, N = 171) or as a first- or second-line therapy as part of the multicenter PROPHECY trial (NCT02269982) (Validation cohort, N = 107). The measured CTC number was then associated with overall survival (OS) in the Discovery cohort, and progression-free survival (PFS) and OS in the Validation cohort. CTC enumeration was also performed on a concurrently obtained blood sample using the CellSearch® Circulating Tumor Cell Kit. In the MSKCC Discovery cohort, CTC count was a statistically significant prognostic factor of OS as a dichotomous (
ISSN:0959-8049
1879-0852
DOI:10.1016/j.ejca.2021.02.042